Audit Trail12 Nov 2026, 14:32AI Screening SystemScreened as Include
55545 included · 2,271 excluded · 8 unclear
Screening Details
Physiotherapy-led group programme for back pain in primary care
Demo Primary Care Journal · 2022 · DOI 10.0000/demo.2022.0932
AI AnalysisAI DecisionUnclearAI Confidence58%
Overall Summary
A physiotherapist-led group exercise programme compared with usual care in primary care. The abstract states neither how long participants had pain nor how they were allocated. Eligibility depends on the full text.
Key Evidence
“weekly physiotherapist-led exercise classes”
“patients were allocated to the programme or usual care”
AI Reasoning 5 Satisfied0 Violated3 Unclear
unclear: Adults with chronic non-specific low back pain Population
The abstract gives no duration of pain.
unclear: Randomised controlled trial Study design
Patients were allocated to groups, the method is not stated.
unclear: Acute or post-surgical back pain Population
Group exercise sessions are led by physiotherapists.
satisfied: Usual care, no treatment or another active treatment Comparator
The comparison is usual care.
satisfied: Pain intensity or disability reported Outcome
Pain and disability are reported at six months.
satisfied: Participants under 18 years Population
All participants are adults.
satisfied: Protocol or conference abstract without results Publication type
Results are reported in full.
Audit TrailAI Screening SystemScreened as Unclear12 Nov 2026, 14:33
Screening Details
Supervised exercise versus usual care in chronic low back pain: a randomised trial
Demo Journal of Musculoskeletal Research · 2023 · DOI 10.0000/demo.2023.1284
AI AnalysisAI DecisionScreeningAI Confidence–
Overall Summary
A randomised trial of supervised exercise against usual care in adults with chronic low back pain. Pain intensity at 12 weeks is the primary outcome. All inclusion criteria are met and no exclusion criterion applies.
Key Evidence
“randomly assigned to a supervised exercise programme or usual care”
“non-specific low back pain lasting 12 weeks or longer”
AI Reasoning 8 Satisfied0 Violated0 Unclear
satisfied: Adults with chronic non-specific low back pain Population
Participants are adults whose pain has lasted 12 weeks or longer.
The programme is delivered in supervised sessions.
satisfied: Usual care, no treatment or another active treatment Comparator
The comparison group receives usual care.
satisfied: Pain intensity or disability reported Outcome
Pain intensity at 12 weeks is the primary outcome.
satisfied: Randomised controlled trial Study design
Participants were randomly assigned to the two groups.
satisfied: Acute or post-surgical back pain Population
Pain is chronic and no surgery is reported.
satisfied: Participants under 18 years Population
All participants are adults.
satisfied: Protocol or conference abstract without results Publication type
Results are reported in full.
Audit TrailAI Screening SystemScreened as Include12 Nov 2026, 14:32
Every AI decision shows its reasoning and confidence · demo data
<1 month
To a draft review with Puraite
16 months
Industry average
The AI does its part in days. With your reviewers checking every decision, you have a full draft in under a month. A typical review takes 16 months.
Supported by Europe's leading AI and life science organisations
Why Puraite
How Puraite differs from generic AI tools and legacy review software.
Every decision shows its reasons.
For every screening decision, the AI lists which criteria are met, unmet or unclear. It quotes the supporting passage when there is one and reports its confidence from 0 to 100%.
We conducted a systematic search of MEDLINE, Embase and Cochrane Central. Eligible trials enrolled adults (≥18 years) with moderate-to-severe rheumatoid arthritis (DAS28 ≥3.2) who received any approved IL-6 receptor inhibitor. Primary endpoint was ACR20 response at week 12.
AI citation: Population criterion
Eligibility Criteria
Adult RA patients (DAS28 ≥3.2)
IL-6 receptor inhibitor arm
RCT or controlled trial design
Min. 12-week follow-up
ACR20 primary endpoint
AI Recommendation: Include
Check each criterion against the highlighted passage · demo data
Every step documented for your dossier.
Your PRISMA 2020 flow diagram builds itself from your screening decisions. The AI pre-fills risk of bias for your assessors to accept or change. GRADE certainty is rated outcome by outcome. Every judgement goes into the audit log.
Records marked as ineligible by automation tools (n = 0)
Records removed for other reasons (n = 0)
Records screened
(n = 1,572)
AI-screened
1,572 (100%)
Human-screened
1,572 (100%)
Records excluded
(n = 1,498)
By AI
1,498
By human
1,492
AI agreement
97%
Reports sought for retrieval
(n = 74)
Reports not retrieved
(n = 3)
Reports assessed for eligibility
(n = 71)
AI-assessed
71
Human-assessed
71
Reports excluded
Wrong population (n = 18)
Wrong intervention (n = 14)
Wrong comparator (n = 9)
Wrong outcome (n = 11)
Wrong study design (n = 13)
Total (n = 65)
AI-excluded
62
Human-excluded
65
Studies included in review
(n = 6)
Quantitative synthesis (n = 6)
Qualitative synthesis (n = 0)
The PRISMA flow diagram builds itself and shows who decided · demo data
A human makes the final call.
People resolve every conflict and can override any AI decision. Each override is logged.
Title & Abstract Screening/Audit TrailRead-only
Supervised exercise versus usual care in chronic low back pain: a randomised trial
AI Screening SystemIncluded, confidence 94%Decision with rationale and source quotes stored
R. Okafor · Reviewer 1IncludedAdopted the AI decision after reading the abstract
L. Brandt · Reviewer 2ExcludedReason given: comparator is another exercise programme
SystemConflict openedTwo human decisions differ, record leaves the queue
M. Sato · Project ManagerConflict resolved: IncludedComparator criterion I3 allows another active treatment
SystemSent to full-text retrievalPRISMA count updated
Who decided what and when, for every record · demo data
The whole review or just the step you need.
Take a review from protocol to PRISMA report in one audited workspace. Already screened elsewhere? Start at data extraction.
Demo organisation/Projects
Start your evidence project
Recommended
Guided Review
Step by step through a complete, audit-ready review.
Best for most reviews
or start another way
Data extraction onlyStandalone statistical analysis
Studies already chosen? Start at data extraction and skip search and screening.
Run the whole review or start at the step you need · demo data
No training on your content
We do not use your content to train or fine-tune AI models. Our AI providers retain inputs only for the periods set out in our data processing agreement. You can export or delete your data. Section 14 of our Terms of Use explains how and when.
A systematic review to evaluate the efficacy of IL-6 inhibitors in patients with moderate-to-severe rheumatoid arthritis, comparing treatment outcomes versus placebo or standard of care.
Extract Criteria
Criteria Board
P
Population
Adults with moderate-to-severe RA
I
Intervention
IL-6 receptor inhibitors
C
Comparison
Placebo or standard of care
O
Outcome
ACR20 response at week 12
Turn your research question into clear eligibility criteria · demo data
Search & Management
Search the open databases from inside the project and import everything else by file.
Efficacy of IL-6 receptor inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis
Demo Journal of Rheumatology · 2024 · 1,847 participants
AI Rationale
Population matches adult RA patients (P criterion met). Intervention aligns with IL-6 inhibitor protocol (I criterion met). Primary outcomes reported at week 12 (O criterion met).
ExcludeInclude
Reviewers decide record by record, with the AI's reasoning beside them · demo data
Extraction & Quality
Dual extraction and risk of bias with the tool that fits the study design.
...enrolled 342 patients across 14 sites. ACR20 response was achieved in 68.4% of patients in the treatment arm vs 28.1% in the placebo arm (p<0.001). Mean DAS28 reduction of 2.1 points
3 fields linked to this passage
Extraction Form
Sample size
342 patients
ACR20 (treatment)
68.4%
ACR20 (placebo)
28.1%
p-value
< 0.001
DAS28 reduction
2.1 points
Every extracted value links back to its source · demo data
Synthesis & Grading
Meta-analysis with forest plots, GRADE and Summary of Findings tables.
01Meta-Analysis
02Qualitative Synthesis
03GRADE Assessment
04Summary of Findings Tables
Projects/GRADE AssessmentEvidence ProfileSummary of Findings
⊕⊕⊕⊕High
⊕⊕⊕○Moderate
⊕⊕○○Low
⊕○○○Very low
HTMLExport
Summary of Findings4/7
Outcome
Studies
Participants
Effect Estimate (CI)
Certainty
Risk with comparator
Absolute effect
Plain Language Summary
ACR20 response at week 12
5
2,068
RR 2.32 (95% CI 1.94 to 2.77)
⊕⊕⊕○Moderate
281 per 1,000
371 more per 1,000 (from 264 more to 497 more)
The intervention probably increases ACR20 response at week 12.
DAS28 remission at week 24
4
1,656
RR 5.02 (95% CI 3.41 to 7.39)
⊕⊕⊕○Moderate
54 per 1,000
217 more per 1,000 (from 130 more to 345 more)
The intervention probably increases DAS28 remission at week 24.
Serious adverse events
6
2,678
RR 1.23 (95% CI 0.89 to 1.70)
⊕⊕○○Low
52 per 1,000
12 more per 1,000 (from 6 fewer to 36 more)
The intervention may result in little to no difference in serious adverse events.
Withdrawal due to adverse events
6
2,678
RR 1.58 (95% CI 1.04 to 2.40)
⊕⊕⊕○Moderate
31 per 1,000
18 more per 1,000 (from 1 more to 43 more)
The intervention probably increases withdrawal due to adverse events.
Certainty of evidence, rated outcome by outcome · demo data
Reporting & Maintenance
PRISMA manuscript draft, flow diagram and checklist.
Universities and public research institutes run their systematic reviews on Puraite. Academic access is free, with no time limit. Run as many reviews as you need.
Harvard UniversityUnited States
University of OxfordUnited Kingdom
National Research and Innovation Agency (BRIN)Indonesia
Universidad de AntioquiaColombia
Università degli Studi della Campania Luigi VanvitelliItaly
University of AberdeenUnited Kingdom
Wayne State UniversityUnited States
All India Institute of Speech and Hearing, MysuruIndia
Puraite's end-to-end systematic review platform has allowed us to maintain a high level of research momentum without compromising human control. It has streamlined our evidence synthesis workflow, allowing our team to process and manage over 10,000 records in an auditable, highly efficient workspace.
We use Puraite to streamline our systematic reviews, particularly for collaborative screening, risk-of-bias assessment, and data extraction. The platform has helped our team organize the review workflow more efficiently and maintain consistency across the stages of the review.
Puraite has helped our research team streamline the full-text retrieval process for our systematic review. This has been valuable in supporting an efficient and systematic approach to evidence synthesis.
We have used Puraite to support the screening workflow of our systematic review, from title and abstract screening through to full-text assessment. The platform has helped us keep the process structured, efficient and transparent, while remaining very intuitive to use.
I have been working with Puraite to run an in-house verification test of a review I am working on in another system and it has been very interesting and accurate.
Puraite has been a very helpful tool in our research.
Researchers at over 150 institutions in over 40 countries
Puraite is built in Bielefeld and Paderborn, Germany. Research teams on every inhabited continent use it.
Germany
Countries where researchers use Puraite · as of November 2026
Australia
Austria
Bahrain
Belgium
Brazil
Canada
Chile
China
Colombia
Cyprus
Denmark
Egypt
Germany
Ghana
India
Indonesia
Ireland
Italy
Jordan
Lebanon
Macao
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Nigeria
Norway
Peru
Poland
Portugal
Romania
Russia
Saint Kitts and Nevis
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Thailand
Türkiye
United Arab Emirates
United Kingdom
United States
What your reviews cost in researcher time
Set your own numbers. The starting values come from a published cost study.
Researcher time saved per year
EUR 500,480
12,512 researcher hours
Researcher hours per year
Today
17,875 h
With Puraite
5,363 h
The starting values follow Michelson and Reuter (Contemporary Clinical Trials Communications, 2019): five co-authors working 15 hours a week for 11 months, about USD 141,000 of researcher time per review. The share of time the AI takes over is your assumption. The Puraite licence is not included.